Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 202
Filtrar
1.
ESMO Open ; 7(2): 100415, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35247869

RESUMO

BACKGROUND: The comprehensive measurement of autoimmune disease-related antibodies (Abs) before immune checkpoint inhibitor (ICI) treatment may be useful for predicting the development of immune-related adverse events (irAEs); however, the clinical utility is not well known. MATERIALS AND METHODS: We retrospectively analyzed patients with advanced solid tumors treated with ICI monotherapy or doublet combination therapy between July 2014 and December 2020 at single institute. Anti-nuclear antibody (ANA), anti-thyroglobulin (Tg) Ab, anti-thyroid peroxidase (TPO) Ab, anti-glutamic acid decarboxylase (GAD) Ab, anti-acetylcholine esterase receptor (AchR) Ab, and platelet-associated immunoglobulin G (PA-IgG) Ab were comprehensively measured for the screening before ICI therapy. RESULTS: Of 275 registered patients (median age, 70 years; male, 64.4%; Eastern Cooperative Oncology Group performance status of 0 or 1, 88.7%; and prior regimen of 0-1/≥2, 88.7%/11.3%), 128 non-small-cell lung cancer, 35 gastric cancer, 33 head and neck cancer, 24 melanoma, 19 renal cell carcinoma, 13 urothelial carcinoma, 12 esophageal cancer, 5 malignant mesothelioma of pleura, 2 endometrial cancer, and 4 other cancer were included. The number of patients with positive ANA, Tg, TPO, PA-IgG, GAD, and AchR Abs was 52 (24.9%), 38 (14.5%), 11 (10.1%), 6 (3.5%), 5 (2.0%), and 1 (0.5%), respectively. There was no association between the development of any irAEs and Abs positivity, while thyroid dysfunction developed more frequently among patients with than without Tg Ab or TPO Ab (39.5% versus 12.5%, P < 0.01; 45.5% versus 14.3%, P = 0.02). CONCLUSIONS: The clinical utility of comprehensive measurement of autoimmune disease-related Abs before introduction of ICI therapy was limited for predicting irAE. However, Tg and TPO Abs were risk factors as regards the development of ICI-induced thyroid dysfunction.


Assuntos
Doenças Autoimunes , Carcinoma Pulmonar de Células não Pequenas , Carcinoma de Células de Transição , Neoplasias Pulmonares , Neoplasias da Bexiga Urinária , Idoso , Doenças Autoimunes/induzido quimicamente , Doenças Autoimunes/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Feminino , Humanos , Inibidores de Checkpoint Imunológico/efeitos adversos , Imunoglobulina G/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Estudos Retrospectivos
2.
Clin Oncol (R Coll Radiol) ; 30(1): e1-e8, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29153625

RESUMO

AIMS: The role of PD-1 (programmed cell death 1) expression on the clinical outcome of upper tract urothelial carcinoma has not yet been elucidated in detail. MATERIALS AND METHODS: PD-1 expression was immunohistochemically examined in 181 upper tract urothelial carcinoma patients who underwent radical nephroureterectomy. A part of PD-1 protein expression in the tumour periphery and tumour nest was evaluated separately. The PD-1-positive cells were counted in the area showing the highest density of PD-1 expression at a magnification of 400×. RESULTS: PD-1 staining in the tumour nest was low in 137 (75.7%) and high in 44 (24.3%) patients. PD-1 staining in the tumour periphery was low in 78 (43.1%) and high in 103 (56.9%) patients. The 5 year progression-free survival rates in patients with the high PD-1 expression in the tumour nest and in the tumour periphery were 54.6% and 67.7%, respectively, which were significantly lower than those in their counterparts (79.4%, P < 0.001; 80.0%, P = 0.04). The 5 year cancer-specific survival rates in patients with the high PD-1 expression in the tumour nest and the tumour periphery were 69.1% and 75.7%, respectively, which were significantly lower than those in their counterparts (84.7%, P = 0.007; 87.8%, P = 0.01). A multivariate Cox regression analysis identified the high PD-1 expression in the tumour nest (hazard ratio 3.07, P < 0.001; hazard ratio 2.44, P = 0.011) and positive lymphovascular invasion (hazard ratio 4.86, P < 0.001; hazard ratio 4.03, P < 0.001) as independent predictors of disease progression and of cancer death, respectively. CONCLUSIONS: PD-1 positivity in the tumour nest could be a strong predictor for a worse clinical outcome and may be a useful indicator for selecting appropriate candidates for adjuvant therapy such as chemotherapy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.


Assuntos
Imuno-Histoquímica/métodos , Nefroureterectomia/métodos , Receptor de Morte Celular Programada 1/metabolismo , Neoplasias Ureterais/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Taxa de Sobrevida , Neoplasias Ureterais/genética , Neoplasias Ureterais/mortalidade , Neoplasias Ureterais/patologia
3.
Transplant Proc ; 49(10): 2251-2255, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29198655

RESUMO

BACKGROUND: We performed a clinical and pathological analysis of cases of acute vascular rejection (AVR), characterized by intimal arteritis and transmural arteritis (Banff v score) after kidney transplantation, in an attempt to clarify the mechanisms underlying the development and prognostic significance of AVR. METHODS: AVR (Banff score: v >0) was diagnosed in 31 renal allograft biopsy specimens (BS) obtained from 31 renal transplant patients receiving follow-up care at the Department of Urology, Tokyo Women's Medical University, between January 2010 and April 2016. RESULTS: AVR was diagnosed at a median of 124.6 days after transplantation. Among the 31 BS showing evidence of AVR, AVR was mild (v1 in Banff's classification) in 25 cases, moderate (v2) in 6, and severe (v3) in none. We classified the 31 BS with evidence of AVR by their overall histopathological features as follows: isolated v lesions were observed in 6 BS, acute antibody-mediated rejection (AAMR) in 7, acute T-cell-mediated rejection (ATCMR) in 12, and both ATCR and AAMR in 6. Loss of the renal allograft occurred during the observation period in 3 patients, and, of the remaining cases with functioning grafts, deterioration of renal allograft function after biopsy occurred in only 2 patients. CONCLUSIONS: The results of our study suggest that ATCMR contributes to AVR in 40% to 60% of cases, AAMR in 20% to 40% of cases, and isolated v lesions in 20% of cases. The prognosis of the patient with the graft that had AVR was relatively good under the present immunosuppression protocol and current anti-rejection therapies.


Assuntos
Arterite/patologia , Rejeição de Enxerto/patologia , Transplante de Rim/efeitos adversos , Rim , Complicações Pós-Operatórias/patologia , Túnica Íntima/patologia , Doença Aguda , Adulto , Arterite/etiologia , Biópsia , Feminino , Seguimentos , Humanos , Rim/irrigação sanguínea , Rim/fisiopatologia , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Prognóstico , Estudos Retrospectivos , Linfócitos T/imunologia
4.
J Endocrinol Invest ; 40(4): 385-389, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27848228

RESUMO

INTRODUCTION: High DNA polymerase ß activity has been observed in the thyroid tissue of patients with Graves' disease (Nagasaka et al. in Metabolism 37:1051-1054, 1988). This fact aroused our interest in whether the alteration of DNA polymerase ß activity depends on DNA polymerase ß (DNA poly ß) mRNA levels, which may be modulated by thyroid-stimulating hormone (TSH) or thyroid-stimulating substances, i.e. TSH receptor antibody (TRAb). RESULT: Addition of TSH or TRAb to primary cultures of Graves' disease thyroid cells for 4 h led to no increase in DNA poly ß mRNA levels. In contrast, thyroid hormone synthesizing enzyme, peroxidase, mRNA levels increased fivefold after coculture with TSH and TRAb, even though DNA poly ß activity and mRNA levels are already significantly higher in Graves' disease thyroid tissues, compared with normal thyroid tissue. DISCUSSION: These results indicate that DNA poly ß expression in Graves' disease thyroid cells may be maximally activated or plateau in response to thyroid-stimulating immunoglobulins, or that the activation of to poly ß expression may occur via pathways other than the G protein and cyclic AMP system.


Assuntos
DNA Polimerase beta/genética , Doença de Graves/enzimologia , RNA Mensageiro/genética , Glândula Tireoide/enzimologia , Autoantígenos/genética , Northern Blotting , Células Cultivadas , Doença de Graves/genética , Doença de Graves/patologia , Humanos , Imunoglobulinas Estimuladoras da Glândula Tireoide/farmacologia , Iodeto Peroxidase/genética , Proteínas de Ligação ao Ferro/genética , Receptores da Tireotropina/imunologia , Glândula Tireoide/patologia , Hormônios Tireóideos/metabolismo , Tireotropina/farmacologia
5.
Clin Oncol (R Coll Radiol) ; 26(12): 781-8, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25179323

RESUMO

AIMS: Granulocyte colony-stimulating factor (G-CSF)-producing upper urinary tract carcinoma is extremely rare, and we do not yet have a comprehensive understanding of the disease. This study was carried out to determine the characteristics of G-CSF-producing upper urinary tract carcinoma. MATERIALS AND METHODS: A systematic MEDLINE and ICHUSHI WEB (Japan Medical Abstract Society) search was carried out to identify articles and conference proceedings describing patients with G-CSF-producing upper urinary tract carcinoma. The final cohort included 46 patients: eight studies were published in English, 16 in Japanese and there were 18 Japanese conference proceedings. RESULTS: The average age of patients was 67 years and the male to female ratio was 2.5 to 1. The mean white blood cell count was as high as 33,900/µl (range 10,000-121,000) in these patients. Pretreatment serum G-CSF levels were measured in 23 patients, all of which were higher (range 55-1220 pg/ml) than normal levels. Metastasis was detected in 29 patients (63%) and lymph node and lung metastases were well observed. The most commonly reported primary treatment was surgery (33 patients), but the median survival period for these patients was short (4.5 months). Multivariate analysis showed that lymph node and/or distant metastasis (hazard ratio 2.92, P = 0.020) and the absence of adjuvant therapy (hazard ratio 3.20, P = 0.014) were independent risk factors for mortality. A total of only seven patients survived more than 1 year and most had a history of neoadjuvant/adjuvant chemotherapy and/or radiation therapy. CONCLUSION: We believe that the presence of G-CSF-induced leukocytosis represents a distinct and highly aggressive form of upper urinary tract carcinoma. However, the results of our systematic review indicate that a multidisciplinary approach including surgery, neoadjuvant or adjuvant chemotherapy and radiotherapy may have the potential to control the disease, although we cannot provide definitive recommendations from this retrospective study.


Assuntos
Fator Estimulador de Colônias de Granulócitos/biossíntese , Neoplasias Urológicas/metabolismo , Idoso , Feminino , Humanos , Japão , Masculino , Estudos Retrospectivos , Neoplasias Urológicas/patologia
6.
Transplant Proc ; 44(3): 680-3, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22483467

RESUMO

OBJECTIVES: We expect that if chronic renal failure (CRF) is improved after renal transplantation (RTx), dialysis osteopathy bone lesions would also recover to normal. Nevertheless, it is controversial whether bone lesions really improve after RTx. In this study, we evaluated whether pathological dialysis osteopathy improved after RTx. MATERIALS AND METHODS: The 84 patients who had undergone living related RTx had also undergone a bone biopsy (Bx) since January 2004, including 13 (16.0%) with a diagnosis of aplastic osteopathy. They included 7 men and 6 women. The average hemodialysis (HD) period was 40.3 months. The immunosuppression was tacrolimus (FK); mycophenalate mofetil (MMF) and steroid. We examined Ca, P, intact-PTH (i-PTH), metabolic bone markers, and bone density (DXA) before and 1 year after RTx. In addition, a Bx was performed after having osteal labeling twice before Bx. In addition 2 cases (15.3%) also underwent a Bx after RTx. RESULTS: All cases survive with well functioning renal grafts. The mean levels of Ca and P before RTx were 8.7 mg/mL and 6.6 mg/dL, respectively. The mean i-PTH level was 137.8 pg/mL before RTx and of alkaline phosphatase (ALP) was 202.1 U/L before RTx. The total density and % age match of DXA before RTx averaged 398.7 mg/ccm and 96.7%, respectively. The mean bone volume fraction (BV/TV: Bone Volume/Tissue Volume) before RTx was 17.2%. The mean osteoid volume (OV/TV) before RTx was 2.7%. The mean fibrosis volume (Fb.V/TV) before RTx was 0%. The mean bone formation rate (BFR/BV) before RTx was 2.1 %/y. Two cases were also pathologically diagnosed as renal osteodystrophy at 1 year after RTx: 1 case was mixed type, and another was osteomalacia, which was accompanied by a lumbar compression fracture (Fx) during the clinical course. CONCLUSIONS: Bone metabolism in patients with aplastic ROD histologically improved at 1 year after RTx, presumably due to good renal transplant function. However, it is unknown whether both hypophosphatemia and decrease of FGF-23 improved bone However, patients with aplastic ROD were not completely normalized histologically at 1 year after RTx.


Assuntos
Doenças Ósseas/patologia , Transplante de Rim , Adulto , Feminino , Fator de Crescimento de Fibroblastos 23 , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade , Diálise Renal , Resultado do Tratamento
7.
Exp Clin Endocrinol Diabetes ; 117(10): 593-9, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19924605

RESUMO

The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15 mg/day) treatment group or a low-dose metformin (500 mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TG), HDL and LDL-cholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administration. Significant decreases in HbA1c and HOMA-IR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbA1c, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Síndrome Metabólica/tratamento farmacológico , Metformina/administração & dosagem , Tiazolidinedionas/administração & dosagem , Adulto , Idoso , Glicemia/efeitos dos fármacos , Glicemia/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Índice de Massa Corporal , Proteína C-Reativa/metabolismo , Diabetes Mellitus Tipo 2/complicações , Feminino , Hemoglobinas Glicadas/metabolismo , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Síndrome Metabólica/complicações , Metformina/efeitos adversos , Pessoa de Meia-Idade , Seleção de Pacientes , Pioglitazona , Radioimunoensaio , Tiazolidinedionas/efeitos adversos , Resultado do Tratamento , Ultrassonografia , Circunferência da Cintura/efeitos dos fármacos
8.
Rheumatology (Oxford) ; 47(11): 1635-40, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18786965

RESUMO

OBJECTIVES: We investigated the influence of cytokines on the expression of RANK ligand (RANKL) in fibroblast-like synoviocytes from RA patients (RA-FLS). METHODS: RA-FLS were stimulated by IL-6, TNF-alpha, IL-17 and IL-1beta with or without soluble IL-6 receptor (sIL-6R) for 24 h. The expression of RANKL was measured by real-time PCR, western blotting and immunostaining. In proliferation assay, RA-FLS were cultured with cytokines for 3 days. RA-FLS were co-cultured with RAW cell in the presence of IL-6/sIL-6R for 3 days and then NFATc1 mRNA expression in RAW cells was examined. RA-FLS was cultured with parthenolide [PAR, signal transducer and activator of transcription (STAT) inhibitor] or PD98059 (PD, mitogen-activated protein kinase inhibitor) in the presence of IL-6/sIL-6R and then the influence of these drugs on phosphorylation of STAT3 and ERK1/2, and RANKL expression was examined. RESULTS: RANKL expression was induced by IL-6/sIL-6R (but not IL-6 alone) and by IL-1beta. On the other hand, TNF-alpha and IL-17 did not induce RANKL expression, although TNF-alpha, IL-17 or IL-1beta stimulated cell growth and IL-6 production. However, in the presence of sIL-6R, TNF-alpha or IL-17 induced RANKL expression. By the co-culture of RA-FLS, NFATc1 mRNA expression was induced in RAW cells. Finally, IL-6/sIL-6R induced phosphorylation of STAT3 and ERK1/2 in RA-FLS, and was completely inhibited by PAR and PD, respectively. PAR completely inhibited IL-6/sIL-6R-induced RANKL expression, but PD did not. CONCLUSIONS: IL-6/sIL-6R directly induced RANKL expression in RA-FLS and it is essential for RANKL induction by TNF-alpha and IL-17. Moreover, RANKL induction by IL-6/sIL-6R is mediated by the janus kinase/STAT signalling pathway.


Assuntos
Artrite Reumatoide/metabolismo , Interleucina-17/farmacologia , Interleucina-6/metabolismo , Ligante RANK/metabolismo , Membrana Sinovial/metabolismo , Fator de Necrose Tumoral alfa/farmacologia , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais Humanizados , Western Blotting/métodos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Fibroblastos , Flavonoides/farmacologia , Humanos , Imuno-Histoquímica , Interleucina-1beta/farmacologia , Interleucina-6/farmacologia , Quinases de Proteína Quinase Ativadas por Mitógeno/antagonistas & inibidores , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Fosforilação/efeitos dos fármacos , Ligante RANK/análise , Ligante RANK/genética , RNA Mensageiro/análise , Receptor Ativador de Fator Nuclear kappa-B/metabolismo , Receptores de Interleucina-6/antagonistas & inibidores , Receptores de Interleucina-6/metabolismo , Proteínas Recombinantes/farmacologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Fator de Transcrição STAT3/metabolismo , Sesquiterpenos/farmacologia , Transdução de Sinais/fisiologia , Estimulação Química , Membrana Sinovial/efeitos dos fármacos
9.
Diabet Med ; 24(11): 1279-81, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17956452

RESUMO

AIMS: A rare case of the insulin autoimmune syndrome (IAS) accompanied by insulin receptor anomaly is reported. METHODS: Antibodies to insulin and insulin receptor were determined in the patient with severe hypoglycaemia before and after the treatment with prednisolone. RESULTS: Titers of antibody to insulin and insulin receptors were 73.0% and 41.5%, respectively. Drug-induced lymphocyte stimulation tests were all negative for the suspicious drugs. Her HLA-DR was DRB1*0403/04051. Following steroid therapy, the formation of antibodies was suppressed and alleviated her symptoms. Scatchard analysis yielded findings specific to polyclonal antibodies. CONCLUSIONS: The changes in autoantibodies resulted in alleviation of the hypoglycemic symptoms as a result of steroid therapy.


Assuntos
Doenças Autoimunes/diagnóstico , Hipoglicemia/diagnóstico , Insulina/metabolismo , Idoso , Doenças Autoimunes/complicações , Doenças Autoimunes/tratamento farmacológico , Glicemia/metabolismo , Feminino , Antígenos HLA-DR , Humanos , Hipoglicemia/complicações , Hipoglicemia/tratamento farmacológico , Anticorpos Anti-Insulina/metabolismo , Secreção de Insulina , Ativação Linfocitária/efeitos dos fármacos , Receptor de Insulina/metabolismo , Resultado do Tratamento
10.
J Neural Transm (Vienna) ; 114(12): 1553-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17676428

RESUMO

We investigated the alteration of oligodendrocytes in comparison with that of astrocytes and microglia in the mouse striatum after MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropridine) treatment under the same conditions using Western blot analysis and Immunohistochemistry. In our Western blot analysis, four administrations of MPTP at 2-h intervals to mice produced the remarkable loss of TH (tyrosine hydroxylase) protein levels in the striatum after 3 and 7 days. In contrast, GFAP (glial fibrillary acidic protein) and Iba-1 protein in the striatum showed a significant increase of GFAP and Iba-1 protein levels 3 and 7 days after MPTP treatment. On the other hand, the levels of CNPase (2', 3'-cyclic nucleotide 3'-phosphodiesterase) protein were decreased significantly in the striatum 3 and 7 days after MPTP treatment. In our immunohistochemical study, a significant decrease in the area of expression of CNPase-positive profiles was observed in the striatum 3 and 7 days after MPTP treatment. These results demonstrate that oligodendrocytes in the striatum are damaged after MPTP treatment. Thus our present findings provide valuable information for the pathogenesis of Parkinson's disease.


Assuntos
Corpo Estriado/efeitos dos fármacos , Corpo Estriado/patologia , Intoxicação por MPTP/patologia , Oligodendroglia/efeitos dos fármacos , Oligodendroglia/patologia , 2',3'-Nucleotídeo Cíclico Fosfodiesterases/efeitos dos fármacos , 2',3'-Nucleotídeo Cíclico Fosfodiesterases/metabolismo , Animais , Astrócitos/efeitos dos fármacos , Astrócitos/patologia , Western Blotting , Proteínas de Ligação ao Cálcio/efeitos dos fármacos , Proteínas de Ligação ao Cálcio/metabolismo , Corpo Estriado/metabolismo , Proteína Glial Fibrilar Ácida/efeitos dos fármacos , Proteína Glial Fibrilar Ácida/metabolismo , Imuno-Histoquímica , Intoxicação por MPTP/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Proteínas dos Microfilamentos , Microglia/efeitos dos fármacos , Microglia/patologia , Oligodendroglia/metabolismo , Tirosina 3-Mono-Oxigenase/efeitos dos fármacos , Tirosina 3-Mono-Oxigenase/metabolismo
11.
J Neural Transm (Vienna) ; 113(12): 1887-94, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16736245

RESUMO

S100beta is a calcium-binding peptide produced by astrocytes. This protein is expressed at high levels in brain and is known as a marker of brain damage. However, little is known about the role of S100beta protein during neuronal damage caused by MPTP. To determine exactly changes of expression of S100beta protein in relation to changes of glial cells, we investigated immunohistochemically the expression of S100beta protein using MPTP-treated mice. The present study showed that tyrosine hydroxylase (TH) immunoreactivity was decreased in the striatum and substantia nigra from 5 h and 1 day after MPTP treatment, respectively. Thereafter, a severe reduction in TH immunoreactivity was observed in the striatum and substantia nigra 1, 3 and 7 days after MPTP treatment. In our double-labeled immunostaining, the number of S100-positive/GFAP-negative cells decreased from 1 day up to 7 days after MPTP treatment. In contrast, the number of double-labeled S100/GFAP-immnoreactive cells increased from 1 day up to 7 days after MPTP treatment. The number of S100beta-positive/GFAP-negative cells also decreased 3 and 7 days after MPTP treatment. In contrast, the number of double-labeled S100beta/GFAP-immunoreactive cells increased from 1 day up to 7 days after MPTP treatment. The present study demonstrates that S100beta/GFAP-positive cells may play some role in the pathogenesis of MPTP-induced dopaminergic neurodegeneration in the striatum. The present results also suggest the presence of the S100beta protein in a subpopulation of GFAP-negative astrocytes in the striatum after MPTP treatment. These results suggest that the modulation of astrocytic activation may offer a novel therapeutic strategy of Parkinson's disease.


Assuntos
Proteína Glial Fibrilar Ácida/metabolismo , Intoxicação por MPTP/metabolismo , Fatores de Crescimento Neural/metabolismo , Proteínas S100/metabolismo , Animais , Imuno-Histoquímica , Intoxicação por MPTP/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neostriado/efeitos dos fármacos , Neostriado/metabolismo , Neostriado/patologia , Degeneração Neural/induzido quimicamente , Degeneração Neural/patologia , Neuroglia/efeitos dos fármacos , Neuroglia/metabolismo , Neuroglia/patologia , Subunidade beta da Proteína Ligante de Cálcio S100 , Fatores de Tempo , Tirosina 3-Mono-Oxigenase/metabolismo
12.
Calcif Tissue Int ; 78(3): 152-61, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16525749

RESUMO

The purpose of this study was to assess whether a nutritional supply of calcium (Ca) could be substituted for alfacalcidol (ALF) administration in preventing bone loss due to estrogen deficiency. Female Wistar-Imamichi rats (8 months old) were ovariectomized (OVX) or sham-operated. OVX rats received ALF administration (0.025, 0.5, or 0.1 microg/kg, p.o., 5 times a week) with standard rodent chow [Ca 1.2%, phosphorus (P) 1.04%], a Ca-enriched diet containing 2%, 4%, or 6% Ca (Ca/P ratio of 2, 4, and 6, respectively), or a Ca/P-enriched diet (Ca/P ratio of 1.2). After 12 weeks of treatment, all rats were killed to harvest the spine, serum, and urine samples. Neither the ALF treatment nor the Ca supplement caused hypercalcemia. In the spine, ALF prevented decreases in bone mineral density (BMD) and compressive strength of lumbar spine induced by OVX. Micro-computed tomographic analysis confirmed that ALF significantly improved the trabecular bone pattern factor and the structure model index and suppressed bone destruction. In contrast, of particular interest, high-dose Ca administration did not have marked effects on bone fragility. Also, when both Ca and P were administered in high doses, BMD and mechanical strength decreased dose-dependently, urinary P excretion significantly increased, and serum parathyroid hormone level increased. Together, it is difficult to adjust the Ca supply through diet alone without disrupting the balance between serum Ca and P levels. Consequently, we conclude that ALF is beneficial for the treatment of osteoporosis, which is not achieved by the use of a Ca supplement.


Assuntos
Conservadores da Densidade Óssea/farmacologia , Densidade Óssea/fisiologia , Cálcio da Dieta/administração & dosagem , Hidroxicolecalciferóis/farmacologia , Osteoporose/tratamento farmacológico , Aminoácidos/urina , Animais , Nitrogênio da Ureia Sanguínea , Densidade Óssea/efeitos dos fármacos , Cálcio/sangue , Cálcio/urina , Cálcio da Dieta/uso terapêutico , Força Compressiva , Creatinina/análise , Creatinina/urina , Relação Dose-Resposta a Droga , Ensaio de Imunoadsorção Enzimática , Feminino , Ovariectomia , Hormônio Paratireóideo/sangue , Fósforo/sangue , Fósforo/urina , Ratos , Ratos Wistar , Tomografia Computadorizada por Raios X
13.
Skin Res Technol ; 12(1): 32-5, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16420536

RESUMO

BACKGROUND/AIMS: The degree of oedema may differ at various sites on the leg. This study evaluated the degree of oedema at the calf, ankle and foot using a three-dimensional measurement system. METHODS: By three-dimensional measurement system using the grid pattern projection method, the effects of four different types of elastic compression stockings on oedema prevention were compared in healthy subjects. RESULTS: Without stockings, a significant increase in the circumference and volume was seen at the ankle and foot in the evening compared with morning values. The average increase in circumference was greater at the foot than that at the ankle. A significant increase in circumference and volume in the evening after a day without stockings disappeared when elastic compression stockings were worn during the day. The coefficient of variation was greater for measurements at the foot than for those at the calf and ankle. CONCLUSION: Oedema develops easily in order of the foot, the ankle and the calf in healthy populations. Elastic stockings, even with a pressure as low as 8 mmHg, are effective on oedema prevention. In measurement at the foot, further developments are necessary to improve this system.


Assuntos
Bandagens , Edema/patologia , Edema/prevenção & controle , Interpretação de Imagem Assistida por Computador/métodos , Dermatopatias/patologia , Dermatopatias/prevenção & controle , Dermatopatias/reabilitação , Adulto , Elasticidade , Feminino , Humanos , Imageamento Tridimensional/métodos , Valores de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Resultado do Tratamento
14.
Abdom Imaging ; 30(5): 518-23, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15688103

RESUMO

BACKGROUND: Advances in gastrointestinal endoscopy have resulted in endoscopic mucosal resection becoming the main therapy for many early gastric cancers confined to the mucosa and, in some cases, of minimal submucosal invasion. Thus, preoperative determination of the depth of the cancer is important. We compared the results of high-frequency ultrasound probe sonography with those of histologic study to clarify the usefulness of identifying of submucosal invasion and determining the depth of early gastric cancer. METHODS: Subjects were 295 patients diagnosed with early gastric cancer who had undergone endoscopic mucosal or surgical resection. High-frequency ultrasound probe sonographic findings were compared with histologic findings. RESULTS: The muscularis mucosae was visualized in 63% of cases of early gastric cancer. By construction on receiver operator characteristics curve, we determined that submucosal invasive cancer could be diagnosed by high-frequency ultrasound probe sonography to a depth of about 600 microm. There was no case in which invasion deeper than 1000 microm was diagnosed as a hypoechoic area limited to the mucosal layer or a fan-shaped hypoechoic area in the submucosal layer. The depth of early gastric cancer was accurately determined in 90% of cases. CONCLUSIONS: High-frequency ultrasound probe is a useful tool for accurately determining the depth of invasion of early gastric cancer when its limitations are understood.


Assuntos
Neoplasias Gástricas/diagnóstico por imagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Distribuição de Qui-Quadrado , Feminino , Gastroscopia , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Estadiamento de Neoplasias , Curva ROC , Sensibilidade e Especificidade , Neoplasias Gástricas/patologia , Ultrassonografia
15.
Horm Metab Res ; 36(7): 458-64, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15305228

RESUMO

Two endothelium-derived factors, endothelin (ET), a vasoconstrictor, and vascular endothelial growth factor (VEGF), an angiogenic factor are thought to be involved in the pathogenesis of diabetic vascular complications. The aim of this study was to determine the effects of an angiotensin II type I (AT-1) receptor antagonist and an ACE inhibitor on the pathogenesis of VEGF and ET-1-mediated kidney disease in STZ-induced diabetic rats. Two days after STZ administration, diabetic rats were treated for 8 weeks with enalapril maleate, an ACE inhibitor, candesartan cilexetil, an AT-1 receptor antagonist, or saline. Urinary albumin and N-acetyl beta-D glucosaminidase (NAG) excretion as well as the VEGF protein content in the kidney were all found to be elevated in diabetic rats. Administration of enalapril maleate or candesartan cilexetil decreased the level of microalbuminuria and NAG excretion in diabetic rats. Administration of enalapril maleate also suppressed the elevated renal VEGF protein content in these animals while candesartan cilexetil treatment had no effect. Serum ET-1 and VEGF levels were unchanged by these treatments. These data support a role for AT-1 receptor antagonists and ACE inhibitors in the prevention of diabetic nephropathy, and suggest that the former may work by reducing renal VEGF levels.


Assuntos
Antagonistas de Receptores de Angiotensina , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Benzimidazóis/farmacologia , Compostos de Bifenilo/farmacologia , Angiopatias Diabéticas/prevenção & controle , Nefropatias Diabéticas/prevenção & controle , Enalapril/farmacologia , Tetrazóis , Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos , Albuminúria/etiologia , Albuminúria/fisiopatologia , Análise de Variância , Animais , Anti-Hipertensivos/farmacologia , Glicemia/metabolismo , Western Blotting , Diabetes Mellitus Experimental/complicações , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/fisiopatologia , Angiopatias Diabéticas/tratamento farmacológico , Nefropatias Diabéticas/tratamento farmacológico , Progressão da Doença , Endotelina-1/sangue , Endotelina-1/efeitos dos fármacos , Endotelina-1/metabolismo , Rim/efeitos dos fármacos , Rim/metabolismo , Rim/patologia , Masculino , Ratos , Ratos Wistar , Estreptozocina , Fator A de Crescimento do Endotélio Vascular/sangue , Fator A de Crescimento do Endotélio Vascular/metabolismo
16.
Br J Cancer ; 91(5): 929-34, 2004 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-15280918

RESUMO

We used 202 cases of stomach cancer and 394 controls nested within the Japan Collaborative Cohort Study For Evaluation of Cancer Risk (JACC study) to investigate whether family history has an independent effect on the risk of stomach cancer after controlling for the Helicobacter pylori infection. A positive history of stomach cancer in one or more first-degree relatives was associated with an increased risk of the disease in women, but not in men after controlling for H. pylori infection and other confounding variables. Women with both a family history and H. pylori infection were associated with more than five-fold increased risk of the disease (OR 5.10, 95% CI 1.58-16.5) compared to those without these factors. These results suggest the existence of inherited susceptibility to the disease in women, and that measurements of H. pylori infection together with the family history allow meaningful evaluation of risk beyond that provided by either factor alone.


Assuntos
Infecções por Helicobacter/epidemiologia , Neoplasias Gástricas/genética , Neoplasias Gástricas/microbiologia , Adulto , Idoso , Animais , Estudos de Casos e Controles , Feminino , Predisposição Genética para Doença , Infecções por Helicobacter/complicações , Helicobacter pylori , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Fatores Sexuais
17.
Exp Clin Endocrinol Diabetes ; 112(7): 390-4, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15239025

RESUMO

AIMS: To confirm whether a prostacyclin (prostaglandin I (2)) affects the increased TNF-alpha concentration in sera of diabetic patients, we measured serum TNF-alpha concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. SUBJECTS AND METHODS: Serum TNF-alpha concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-alpha. RESULTS: In diabetic patients, serum TNF-alpha concentration was significantly increased compared with that of healthy subjects. The augmented TNF-alpha concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin I (2)) analogue for 5 weeks without any changes of blood glucose levels. CONCLUSIONS: Stable prostacyclin analogue administration for a short term period reduced increased TNF-alpha levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.


Assuntos
Diabetes Mellitus Tipo 2/sangue , Epoprostenol/análogos & derivados , Epoprostenol/uso terapêutico , Fator de Necrose Tumoral alfa/análise , Adulto , Idoso , Glicemia/análise , Índice de Massa Corporal , Diabetes Mellitus Tipo 2/tratamento farmacológico , Neuropatias Diabéticas/tratamento farmacológico , Feminino , Hemoglobinas Glicadas/análise , Humanos , Masculino , Pessoa de Meia-Idade
18.
Br J Cancer ; 90(7): 1397-401, 2004 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-15054462

RESUMO

The relationship between bowel movement (BM) frequency and the risk of colorectal cancer was examined in a large cohort of 25 731 men and 37 198 women living in 24 communities in Japan. At enrolment, each participant completed a self-administrated questionnaire on BM frequency and laxative use. Incidence rate ratios (IRR) with 95% confidence intervals (CI) were estimated using Cox's proportional-hazard model. During the follow-up period (average length 7.6 years), 649 cases of colorectal cancer, including 429 cases of colon cancer, were identified. Among women, subjects who reported a BM every 2-3 days had the lowest risk of developing colorectal (IRR=0.71, 95% CI=0.52-0.97) and colon cancer (IRR=0.70, 95% CI=0.49-1.00), whereas those reporting a BM every 6 days or less had an increased risk of developing colorectal (IRR=2.47, 95% CI=1.01-6.01) and colon cancer (IRR=2.52, 95% CI=0.93-6.82) compared with those reporting >or=1 BM per day. A similar, but nonsignificant, association between the frequency of BM and cancer risk was observed in men. There was no association between colorectal or colon cancer risk and laxative use. Regulating BM frequency might therefore have a role in the prevention of colorectal cancer.


Assuntos
Neoplasias Colorretais/epidemiologia , Defecação , Adulto , Estudos de Coortes , Feminino , Humanos , Incidência , Japão/epidemiologia , Masculino , Estudos Prospectivos , Risco
19.
Int J Obes Relat Metab Disord ; 28(4): 551-8, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-14968128

RESUMO

OBJECTIVE: To determine whether body size measurements are risk factors for colon cancer death among the Japanese. DESIGN AND SUBJECTS: A nationwide prospective study, the Japan Collaborative Cohort (JACC) Study from 1988 to 1999. The present analysis included 43 171 men and 58 775 women aged 40-79 y who respond to a questionnaire on current weight and height, weight around 20 y of age, and other lifestyle factors. Body mass index (BMI) at baseline and 20 y of age (B-BMI and 20-BMI, respectively) were calculated. RESULTS: We identified 127 deaths from colon cancer during the follow-up of 424 698 person-years among men and 122 deaths during the follow-up of 591 787 person-years among women. After adjustments for the lifestyle factors known to modify the risk of colon cancer, weight at baseline showed a significant positive association in women, while no such association was seen in men. There was also a significant trend of increasing risk with the increase in B-BMI among women. Women with B-BMI >/=28 kg/m(2) had a relative risk (RR) of 3.41 (95% confidence interval (CI): 1.44-8.06) compared with those with BMI of 20-<22 kg/m(2). 20-BMI also presented the same trend of increasing risk as B-BMI. Women with 20-BMI of <22 and B-BMI of >26 kg/m(2), that is, excessive BMI gain, had a high RR of 3.41 (95% CI 1.29-9.02) compared with those with 20-BMI of <22 and B-BMI of <22 kg/m(2). There were no corresponding trends of colon cancer risk for B-BMI, 20-BMI, or BMI change among men. CONCLUSIONS: These study data suggest that obesity and excessive weight gain are associated with the risk of colon cancer death in Japanese women but no such relationship was found in Japanese men.


Assuntos
Constituição Corporal , Neoplasias do Colo/mortalidade , Adulto , Idoso , Estatura , Índice de Massa Corporal , Peso Corporal , Neoplasias do Colo/etiologia , Neoplasias do Colo/fisiopatologia , Feminino , Seguimentos , Humanos , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Obesidade/complicações , Estudos Prospectivos , Fatores de Risco , Fatores Sexuais
20.
Br J Cancer ; 90(1): 135-8, 2004 Jan 12.
Artigo em Inglês | MEDLINE | ID: mdl-14710220

RESUMO

To evaluate whether green tea consumption provides protection against stomach cancer, the relative risks (RRs) were calculated in the Japan Collaborative Study for Evaluation of Cancer Risk, sponsored by the Ministry of Health and Welfare (JACC Study). The study was based on 157 incident cases and 285 controls aged 40-79 years. Cox proportional hazards regression analysis was used to estimate the RRs for stomach cancer. It was found that green tea consumption had no protective effect against stomach cancer. After adjustment for age, smoking status, H. pylori infection, history of peptic ulcer, and family history of stomach cancer along with certain dietary elements, the risks associated with drinking one or two, three or four, five to nine, and 10 or more cups of green tea per day, relative to those of drinking less than one cup per day, were 1.3 (95% confidence interval (CI): 0.6-2.8), 1.0 (95% CI: 0.5-1.9), 0.8 (95% CI: 0.4-1.6), and 1.2 (95% CI: 0.6-2.5), respectively (P for trend=0.899). We found no inverse association between green tea consumption and the risk of stomach cancer.


Assuntos
Neoplasias Gástricas/prevenção & controle , Chá , Adulto , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Incidência , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise de Regressão , Neoplasias Gástricas/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...